Warmly welcomed by Naresuan University executives led by Assoc. Prof. Dr. Sarintip Tantanee, President of Naresuan University (NU), Dr. Phongsthorn Chotikasemsri, CEO and Founder of Welala Co., Ltd. Thailand and Dr. Her Zhizheng, representative of InvitroCue Pte Ltd. Singapore attended a trilateral MOU signing among the three parties to collaborate in exchange of research know-hows, pre-clinical and clinical research, including animal model for cancer studies. Welala Thailand focuses on healthcare and wellness in 4 key areas; i.e., longevity, diagnostic, oncology and pharmacology. The company, although established for 3 years, is capable of producing medical health kits certified by Thai FDA and expanding its connection and market to Singapore for personalized cancer screening test to reduce unfavourable side effects from medication taken by cancer patients. InvitroCue Singapore, founded in 2012 before spanning to subordinate body InvivoCue in 2018 whose expertise is contributed to the use of humanised mice (Hi-Mice) for for medical experimentation research, has its branch companies located around the globe such as Hong Kong, Spain, Australia, Brazil and the U.S. InvitroCue is dedicated to next generation sequence-based personalized medicine and oncology personalized drug screen platform for cancer patients. This cooperation is significantly seen as a move forward to research expansion where NU, in cooperation with Welala and InvitroCue could serve as a hub for newly developed medicine and experimentation.
The ceremony was organized on Monday, 2 December 2024 at 10.00 at Naresuan Meeting Room 301, Office of the President.
